9
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      CT-based deep learning radiomics and hematological biomarkers in the assessment of pathological complete response to neoadjuvant chemoradiotherapy in patients with esophageal squamous cell carcinoma: A two-center study

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Highlights

          • A two-center study showed that deep learning radiomics analysis of pre- and post-nCRT CT images could improve the pCR prediction of patients with ESCC.

          • The combined model was superior to the clinical and radiomics models in predicting pCR in locally advanced ESCC and the LR classifier performed best in the current study.

          • Decision curves demonstrated that the novel predictive model based on deep learning and handcrafted radiomics features combined with hematological parameters has great clinical utility.

          Abstract

          Purpose

          To evaluate and validate CT-based models using pre- and posttreatment deep learning radiomics features and hematological biomarkers for assessing esophageal squamous cell carcinoma (ESCC) pathological complete response (pCR) after neoadjuvant chemoradiotherapy (nCRT).

          Material and methods

          This retrospective study recruited patients with biopsy-proven ESCC who underwent nCRT from two Chinese hospitals between May 2017 and May 2022, divided into a training set (hospital I, 111 cases), an internal validation set (hospital I, 47 cases), and an external validation set (hospital II, 33 cases). We used minimum redundancy maximum relevance (mRMR) and least absolute shrinkage and selection operator (LASSO) as feature selection methods and three classifiers as model construction methods. The assessment of models was performed using area under the receiver operating characteristic (ROC) curve (AUC) and decision curve analysis (DCA).

          Results

          A total 190 patients were included in our study (60.8 ± 7.08 years, 133 men), and seventy-seven of them (40.5 %) achieved pCR. The logistic regression (LR)-based combined model incorporating neutrophil to lymphocyte ratio, lymphocyte to monocyte ratio, albumin, and radscores performed well both in the internal and external validation sets with AUCs of 0.875 and 0.857 (95 % CI, 0.776–0.964; 0.731–0.984, P <0.05), respectively. DCA demonstrated that nomogram was useful for pCR prediction and produced clinical net benefits.

          Conclusion

          The incorporation of radscores and hematological biomarkers into LR-based model improved pCR prediction after nCRT in ESCC. Enhanced pCR predictability may improve patients selection before surgery, providing clinical application value for the use of active surveillance.

          Related collections

          Most cited references47

          • Record: found
          • Abstract: found
          • Article: not found

          Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

          This article provides an update on the global cancer burden using the GLOBOCAN 2020 estimates of cancer incidence and mortality produced by the International Agency for Research on Cancer. Worldwide, an estimated 19.3 million new cancer cases (18.1 million excluding nonmelanoma skin cancer) and almost 10.0 million cancer deaths (9.9 million excluding nonmelanoma skin cancer) occurred in 2020. Female breast cancer has surpassed lung cancer as the most commonly diagnosed cancer, with an estimated 2.3 million new cases (11.7%), followed by lung (11.4%), colorectal (10.0 %), prostate (7.3%), and stomach (5.6%) cancers. Lung cancer remained the leading cause of cancer death, with an estimated 1.8 million deaths (18%), followed by colorectal (9.4%), liver (8.3%), stomach (7.7%), and female breast (6.9%) cancers. Overall incidence was from 2-fold to 3-fold higher in transitioned versus transitioning countries for both sexes, whereas mortality varied <2-fold for men and little for women. Death rates for female breast and cervical cancers, however, were considerably higher in transitioning versus transitioned countries (15.0 vs 12.8 per 100,000 and 12.4 vs 5.2 per 100,000, respectively). The global cancer burden is expected to be 28.4 million cases in 2040, a 47% rise from 2020, with a larger increase in transitioning (64% to 95%) versus transitioned (32% to 56%) countries due to demographic changes, although this may be further exacerbated by increasing risk factors associated with globalization and a growing economy. Efforts to build a sustainable infrastructure for the dissemination of cancer prevention measures and provision of cancer care in transitioning countries is critical for global cancer control.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Immunity, inflammation, and cancer.

            Inflammatory responses play decisive roles at different stages of tumor development, including initiation, promotion, malignant conversion, invasion, and metastasis. Inflammation also affects immune surveillance and responses to therapy. Immune cells that infiltrate tumors engage in an extensive and dynamic crosstalk with cancer cells, and some of the molecular events that mediate this dialog have been revealed. This review outlines the principal mechanisms that govern the effects of inflammation and immunity on tumor development and discusses attractive new targets for cancer therapy and prevention. 2010 Elsevier Inc. All rights reserved.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Cancer-related inflammation.

              The mediators and cellular effectors of inflammation are important constituents of the local environment of tumours. In some types of cancer, inflammatory conditions are present before a malignant change occurs. Conversely, in other types of cancer, an oncogenic change induces an inflammatory microenvironment that promotes the development of tumours. Regardless of its origin, 'smouldering' inflammation in the tumour microenvironment has many tumour-promoting effects. It aids in the proliferation and survival of malignant cells, promotes angiogenesis and metastasis, subverts adaptive immune responses, and alters responses to hormones and chemotherapeutic agents. The molecular pathways of this cancer-related inflammation are now being unravelled, resulting in the identification of new target molecules that could lead to improved diagnosis and treatment.
                Bookmark

                Author and article information

                Contributors
                Journal
                Transl Oncol
                Transl Oncol
                Translational Oncology
                Neoplasia Press
                1936-5233
                13 October 2023
                January 2024
                13 October 2023
                : 39
                : 101804
                Affiliations
                [a ]Shandong University Cancer Center, Shandong University, Jinan, Shandong, China
                [b ]Department of Radiation Oncology Physics and Technology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China
                [c ]Department of Radiation Oncology, Anyang Tumor Hospital, Anyang, Henan, China
                [d ]Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China
                [e ]Department of Radiology, Beijing YouAn Hospital, Capital Medical University, Beijing, China
                [f ]School of Mechanical, Electrical and Information Engineering, Shandong University, Weihai, Shandong, China
                [g ]Manteia Technologies Co., Ltd, Xiamen, Fujian, China
                Author notes
                [* ]Corresponding author at: Department of Radiation Oncology Physics and Technology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China. zhenjli1987@ 123456163.com
                [** ]Corresponding author at: Shandong University Cancer Center, Shandong University, Jinan, Shandong, China; Department of Radiation Oncology Physics and Technology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China. yinyongsd@ 123456126.com
                Article
                S1936-5233(23)00190-0 101804
                10.1016/j.tranon.2023.101804
                10587766
                37839176
                ae844496-3b06-4c51-b332-4d8b425e784b
                © 2023 Published by Elsevier Inc.

                This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

                History
                : 12 July 2023
                : 11 September 2023
                : 9 October 2023
                Categories
                Original Research

                esophageal squamous cell carcinoma,neoadjuvant chemoradiotherapy,pathological complete response,radiomics,machine learning,computed tomography

                Comments

                Comment on this article